Andrea Steck MD

Dr. Steck joined the faculty of BDC in 2008. Her primary research focus is in the area of epidemiology, prediction and prevention of type 1 diabetes (T1D). She has a background in pediatric endocrinology, with specific training and expertise in pediatric diabetes. Her research experience includes work with epidemiological studies such as DAISY (Diabetes Autoimmunity Study in the Young) and TEDDY (The Environmental Determinants of Diabetes in the Young). Dr. Steck is the PI for an ADA Career Development Award on Determinants of rate of progression to T1D in TrialNet subjects at risk of developing diabetes as well as PI of the Twin Family Study. She is also the Colorado PI for several multisite research studies (observational studies, prevention and intervention trials), including SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes, the TrialNet Pathway to Prevention Study, the Hydroxychloroquine (HCQ) for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-Risk for Type 1 Diabetes Mellitus Trial and the LIFT (Long-Term Investigative Follow-Up in TrialNet) Study, as well as the JDRF Follow-up of Children Diagnosed with Diabetes Study, looking at preservation of C-peptide over time in children diagnosed with T1D through TEDDY compared to a group of age matched T1D subjects from the community. In addition, she is the PI and Program Director of the K12-funded career development program for pediatric endocrinologists pursuing diabetes research at the Barbara Davis Center. Her goal is to further characterize staging of risk for T1D, pathophysiology and biomarkers of T1D, preservation of endogenous insulin secretion and eventually prevention of T1D in collaboration with local and national colleagues.